No Data
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), will market Beigene's (SHA: 688235, HKG:6160) oncology medicines, Tislelizumab and Zanubrutinib, in India, acco
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene, Ltd. BGNE is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.
Clinical research tool book “Everything is Visible” officially published and sold
BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched. “Everything is Visible” book cover “Everything Visible” is a systematic introduction to how data visualization can be applied to clinical medical research
Weekend Readings | Buffett's “mysterious” holdings are in Chubb Insurance, losing Munger's Daily Journal and starting to cut back...
This article analyzes 10 “investment giants” including Berkshire Hathaway, The Daily Journal, Gao Lin HLR, Jing Lin, Qiaoshui, Baillie Gifford, ARK, Fisher Price, and Pershing Plaza.
Wall Street bosses are optimistic about China Securities! Not only Bank of America and Temasek, but also these star funds have greatly increased their positions
① In the first quarter of this year, many foreign-funded institutions bought Chinese securities or related ETFs in a big way, showing their confidence in China's asset prospects; ② Chinese internet giants such as Pinduoduo, Ali, JD, and Baidu became their favorite targets.
BeiGene (06160) grants share options to subscribe for a total of 12,000 American Depositary Shares under the 2016 Options and Incentive Plan
BeiGene (06160) issued an announcement. On May 10, 2024, the Remuneration Committee of the Board of Directors was based on 201...